Exploring the effect of APOE ε4 on biomarkers of neurodegeneration in Alzheimer's disease.
Clin Chim Acta
; 562: 119876, 2024 Aug 15.
Article
in En
| MEDLINE
| ID: mdl-39025198
ABSTRACT
BACKGROUND AND AIMS:
This study aims to assess the association between APOE genotype and biomarkers of neurodegeneration in Alzheimer's disease (AD).METHODS:
We performed a retrospective observational study at the University Hospital "P. Giaccone" in Palermo, Italy. We enrolled patients with cognitive decline, including AD. For each patient, we measured amyloid beta (Aß)42, Aß40, tau protein phosphorylated at threonine 181 (pTau), total tau (tTau), neurogranin, alpha-synuclein, and neurofilament light chain (NfL) in cerebrospinal fluid (CSF).RESULTS:
The study population consisted of 194 patients (123 AD and 71 non-AD). AD patients have significantly lower Aß42 levels and Aß42/40 ratio and higher pTau, tTau, and NfLs levels than non-AD patients. In AD patients, the APOEε4 allele is associated with a significantly lower Aß42/40 ratio and higher levels of pTau, tTau, neurogranin, and alpha-synuclein. This association is not observed in non-AD patients.CONCLUSIONS:
This study provides evidence of the significant impact of the APOE ε4 allele on neurodegenerative biomarkers in AD patients, highlighting its role in exacerbating amyloid and tau pathology as well as synaptic degeneration.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers
/
Apolipoprotein E4
/
Alzheimer Disease
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Chim Acta
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: